Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Sales (2024 - 2025)

Historic Return on Sales for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to 43.13%.

  • Prime Medicine's Return on Sales rose 2081500.0% to 43.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.39%, marking a year-over-year increase of 2406700.0%. This contributed to the annual value of 65.67% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Return on Sales is 43.13%, which was up 2081500.0% from 47.17% recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Return on Sales registered a high of 19.37% during Q4 2024, and its lowest value of 367.92% during Q2 2024.